Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
11/22/2024 | $125.00 → $140.00 | Outperform | Oppenheimer | |
11/22/2024 | Hold | Needham | ||
11/22/2024 | $95.00 → $135.00 | Neutral → Outperform | Robert W. Baird | |
11/21/2024 | Outperform → Mkt Perform | William Blair | ||
11/19/2024 | $130.00 | Buy | Berenberg | |
11/19/2024 | $110.00 → $125.00 | In-line → Outperform | Evercore ISI | |
11/12/2024 | $95.00 | Hold | Loop Capital | |
11/8/2024 | $90.00 → $137.00 | Neutral → Buy | Goldman |
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4 - MARKETWISE, INC. (0001805651) (Issuer)
4 - Victoria's Secret & Co. (0001856437) (Issuer)
For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of
Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:
Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:
8-K - Elastic N.V. (0001707753) (Filer)
144 - Marvell Technology, Inc. (0001835632) (Subject)
144 - Marvell Technology, Inc. (0001835632) (Subject)
Oppenheimer reiterated coverage of Elastic with a rating of Outperform and set a new price target of $140.00 from $125.00 previously
Needham initiated coverage of lululemon athletica with a rating of Hold
Robert W. Baird upgraded Elastic from Neutral to Outperform and set a new price target of $135.00 from $95.00 previously
Q2 Revenue of $365 million, up 18% year-over-year (17% in constant currency) Q2 Elastic Cloud Revenue of $169 million, up 25% year-over-year (25% in constant currency) Announces Chief Financial Officer Transition Elastic (NYSE:ESTC) ("Elastic"), the company behind Elasticsearch®, announced financial results for its second quarter of fiscal 2025 ended October 31, 2024. Second Quarter Fiscal 2025 Financial Highlights Total revenue was $365 million, an increase of 18% year-over-year, or 17% on a constant currency basis Elastic Cloud revenue was $169 million, an increase of 25% year-over-year, as reported and on a constant currency basis GAAP operating loss was $4 million; GAAP
Ulta Beauty, Inc. (NASDAQ:ULTA) today announced that its financial results for the third quarter of fiscal 2024 will be released Thursday, December 5, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. ET / 3:30 p.m. CT to discuss the financial results. Investors and analysts who are interested in participating in the call are invited to dial (877) 704-4453. Participants may also listen to a real-time audio webcast of the conference call by visiting the Investor Relations section of the Company's website located at https://www.ulta.com/investor. A replay will be made available online approximately two hours following the live call for a period of 30 days.
lululemon athletica inc. (NASDAQ:LULU) today announced that its financial results for the third quarter fiscal 2024 will be released Thursday, December 5, 2024. The company will host a conference call at 4:30 p.m. Eastern time to discuss the financial results. If you would like to participate in the call, please dial (844) 763-8274 or (647) 484-8814, if calling internationally, approximately 10 minutes prior to the start of the call. A live webcast of the conference call will be available online at: https://corporate.lululemon.com/investors/news-and-events/events-and-presentations. A replay will be made available online approximately 2 hours following the live call. About lululemon at
SC 13G/A - Victoria's Secret & Co. (0001856437) (Subject)
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13G/A - Elastic N.V. (0001707753) (Subject)
Q2 Revenue of $365 million, up 18% year-over-year (17% in constant currency) Q2 Elastic Cloud Revenue of $169 million, up 25% year-over-year (25% in constant currency) Announces Chief Financial Officer Transition Elastic (NYSE:ESTC) ("Elastic"), the company behind Elasticsearch®, announced financial results for its second quarter of fiscal 2025 ended October 31, 2024. Second Quarter Fiscal 2025 Financial Highlights Total revenue was $365 million, an increase of 18% year-over-year, or 17% on a constant currency basis Elastic Cloud revenue was $169 million, an increase of 25% year-over-year, as reported and on a constant currency basis GAAP operating loss was $4 million; GAAP
Ulta Beauty, Inc. (NASDAQ:ULTA) today announced that its financial results for the third quarter of fiscal 2024 will be released Thursday, December 5, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. ET / 3:30 p.m. CT to discuss the financial results. Investors and analysts who are interested in participating in the call are invited to dial (877) 704-4453. Participants may also listen to a real-time audio webcast of the conference call by visiting the Investor Relations section of the Company's website located at https://www.ulta.com/investor. A replay will be made available online approximately two hours following the live call for a period of 30 days.
lululemon athletica inc. (NASDAQ:LULU) today announced that its financial results for the third quarter fiscal 2024 will be released Thursday, December 5, 2024. The company will host a conference call at 4:30 p.m. Eastern time to discuss the financial results. If you would like to participate in the call, please dial (844) 763-8274 or (647) 484-8814, if calling internationally, approximately 10 minutes prior to the start of the call. A live webcast of the conference call will be available online at: https://corporate.lululemon.com/investors/news-and-events/events-and-presentations. A replay will be made available online approximately 2 hours following the live call. About lululemon at
4 - Chemours Co (0001627223) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
PVH Corp. (NYSE:PVH) today announced the appointment of Jesper Andersen, Executive Vice President and Chief Financial Officer of the LEGO Group, to its Board of Directors, effective immediately. He has also been appointed to the Board's Audit and Risk Management Committee. Stefan Larsson, PVH Chief Executive Officer, said, "Jesper is a seasoned global leader with deep experience driving sustainable, brand-accretive growth at one of the most iconic, high-performing consumer brands in the world. Jesper's very strong financial acumen, omnichannel experience and data-driven approach make him an excellent addition to our Board of Directors as we pursue our vision to build Calvin Klein and Tomm
Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B